Processa Pharmaceuticals, Inc. Noncash or Part Noncash Acquisition, Debt Assumed
Processa Pharmaceuticals, Inc. (PCSA) reported Noncash or Part Noncash Acquisition, Debt Assumed of $229.98 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-09-25.
Discontinued › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1 · last filed 2017-09-25
- Processa Pharmaceuticals, Inc. noncash or part noncash acquisition, debt assumed for the quarter ending 2016-09-30 was $229.98K.
- Processa Pharmaceuticals, Inc. noncash or part noncash acquisition, debt assumed for fiscal 2016 was $229.98K.
| Period end | Noncash or Part Noncash Acquisition, Debt Assumed 3 month | Noncash or Part Noncash Acquisition, Debt Assumed 12 month |
|---|---|---|
| 2016-12-31 | $229.98K 10-K · filed 2017-09-25 | |
| 2016-09-30 | $229.98K 10-Q · filed 2017-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |